A Phase III Randomized Trial of Gemcitabine Cisplatin and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed Advanced Biliary Tract Cancers
Brief description of study
If you have been newly diagnosed with advanced biliary tract cancers (cholangiocarcinoma or gallbladder cancer), you may qualify to participate in this study. The main purpose of this phase III trial is to evaluate the investigational drug, nab-Paclitaxel (a microtubule inhibitor) in combination with Gemcitabine (nucleoside analog) and cisplatin (interferes with DNA replication) vs. gemcitabine and cisplatin only. The study will evaluate how well you do on either regimen.
Clinical Study Identifier: s19-00539
ClinicalTrials.gov Identifier: NCT03768414
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
